drugset / Trial / NCT00522886
Phase I Cetuximab and Concurrent Radio-chemotherapy
Phase 1
Completed
24 enrolled
Maastricht Radiation Oncology
Academisch Ziekenhuis Maastricht · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
To determine the MTD toxicity of standard dose cetuximab together with concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine
Timeline
- Start
- 2007-04
- Primary completion
- 2011-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |